User profiles for Emily G. McDonald
Emily G. McDonald MD MSCAssociate Professor of Medicine; McGill University; Scientific Director, CADEN Verified email at mcgill.ca Cited by 6852 |
[HTML][HTML] A randomized trial of hydroxychloroquine as postexposure prophylaxis for Covid-19
Background Coronavirus disease 2019 (Covid-19) occurs after exposure to severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2). For persons who are exposed, the …
respiratory syndrome coronavirus 2 (SARS-CoV-2). For persons who are exposed, the …
Hydroxychloroquine in nonhospitalized adults with early COVID-19: a randomized trial
Background: No effective oral therapy exists for early coronavirus disease 2019 (COVID-19).
Objective: To investigate whether hydroxychloroquine could reduce COVID-19 severity in …
Objective: To investigate whether hydroxychloroquine could reduce COVID-19 severity in …
Comparison of saliva and nasopharyngeal swab nucleic acid amplification testing for detection of SARS-CoV-2: a systematic review and meta-analysis
…, M Yao, N Dendukuri, EG McDonald… - JAMA internal …, 2021 - jamanetwork.com
Importance Nasopharyngeal swab nucleic acid amplification testing (NAAT) is the noninvasive
criterion standard for diagnosis of coronavirus disease 2019 (COVID-19). However, it …
criterion standard for diagnosis of coronavirus disease 2019 (COVID-19). However, it …
Hydroxychloroquine and chloroquine for treatment of SARS-CoV-2 (COVID-19)
…, R Rajasingham, EG McDonald… - Open forum …, 2020 - academic.oup.com
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a rapidly emerging viral
infection causing coronavirus disease 2019 (COVID-19). Hydroxychloroquine and …
infection causing coronavirus disease 2019 (COVID-19). Hydroxychloroquine and …
Continuous proton pump inhibitor therapy and the associated risk of recurrent Clostridium difficile infection
EG McDonald, J Milligan, C Frenette… - JAMA internal …, 2015 - jamanetwork.com
Importance Clostridium difficileinfection (CDI) is associated with significant morbidity, mortality,
and a high risk of recurrence. Proton pump inhibitor (PPI) use is associated with an initial …
and a high risk of recurrence. Proton pump inhibitor (PPI) use is associated with an initial …
Hydroxychloroquine as pre-exposure prophylaxis for coronavirus disease 2019 (COVID-19) in healthcare workers: a randomized trial
…, BI Rini, IA Mayer, EG McDonald… - Clinical Infectious …, 2021 - academic.oup.com
Background Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a rapidly
emerging virus causing the ongoing coronavirus disease 2019 (COVID-19) pandemic with no …
emerging virus causing the ongoing coronavirus disease 2019 (COVID-19) pandemic with no …
[HTML][HTML] Staphylococcus aureus bacteraemia mortality: a systematic review and meta-analysis
…, C Fogarty, G Butler-Laporte, EG McDonald… - Clinical Microbiology …, 2022 - Elsevier
… Lee and Emily G. McDonald receive research salary support from the Fonds de recherche
du Québec–Santé. Mark Loeb reports having served on advisory boards for Sanofi, Pfizer, …
du Québec–Santé. Mark Loeb reports having served on advisory boards for Sanofi, Pfizer, …
Clinical outcomes for patients with anosmia 1 year after COVID-19 diagnosis
…, C Thibault, F Le Normand, EG Mcdonald… - JAMA network …, 2021 - jamanetwork.com
Since the pandemic was declared in early 2020, COVID-19–related anosmia quickly emerged
as a telltale sign of infection. 1, 2 However, the time course and reversibility of COVID-19–…
as a telltale sign of infection. 1, 2 However, the time course and reversibility of COVID-19–…
Fluvoxamine for outpatient management of COVID-19 to prevent hospitalization: a systematic review and meta-analysis
Importance Widely available and affordable options for the outpatient management of COVID-19
are needed, particularly for therapies that prevent hospitalization. Objective To perform …
are needed, particularly for therapies that prevent hospitalization. Objective To perform …
Inhaled and intranasal ciclesonide for the treatment of covid-19 in adult outpatients: CONTAIN phase II randomised controlled trial
Objective To determine if inhaled and intranasal ciclesonide are superior to placebo at
decreasing respiratory symptoms in adult outpatients with covid-19. Design Randomised, double …
decreasing respiratory symptoms in adult outpatients with covid-19. Design Randomised, double …